Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US08659B1026
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00JNGG9Q2
BBNX
Beta Bionics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Beta Bionics, Inc.
ISIN
US08659B1026
TICKER
BBNX
MIC
XNAS
REUTERS
BBNX.OQ
BLOOMBERG
BBNX US
Do., 29.01.2026       Beta Bionics
US08659B1026

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Do., 29.01.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Di., 27.01.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Fr., 23.01.2026       Beta Bionics
US08659B1026

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Do., 22.01.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Mo., 19.01.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Fr., 16.01.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Do., 15.01.2026       Beta Bionics
US08659B1026

IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will hos...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Do., 15.01.2026       Beta Bionics
US08659B1026

LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or faile...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Do., 15.01.2026       Beta Bionics
US08659B1026

 LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) for violations of the securities laws....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 14.01.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Beta Bionics to Contact Him Directly to Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Beta Bionics
US08659B1026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112145401/en/ Faruqi & Faruqi is a leading national sec...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Beta Bionics
US08659B1026

The Law Offices of Frank R. Cruz announces an investigation of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BETA BIONICS, INC. (BBNX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A C...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Beta Bionics
US08659B1026

The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to in...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Sa., 10.01.2026       Beta Bionics
US08659B1026

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       Beta Bionics
US08659B1026

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.11.2025       Beta Bionics
US08659B1026

IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time):...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Beta Bionics
US08659B1026

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Beta Bionics
US08659B1026

IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Do., 19.06.2025       Beta Bionics
US08659B1026

IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 25.03.2025       Beta Bionics
US08659B1026

IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025....
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink
Fr., 31.01.2025       Beta Bionics
US08659B1026

IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters’ option to purchase 1,800,00...
Zur Nachricht
Beta Bionics
Charts & Research Termsheets Terminal
Permalink